Table 1.
Aberrant TRAP1 expression in different tumors.
| Lineage | Cancer subtype | No. of samples | TRAP1 expression characteristics | Ref. |
|---|---|---|---|---|
| Nasopharynx | Nasopharyngeal carcinoma (NPC) | 56 | Higher expression in NPC tissues than in normal noncancerous nasopharyngeal tissues | (14) |
| Colorectum | Colorectal adenocarcinoma | 714 | Positive correlation with the pathological T stage | (15) |
| Prostate | Prostate cancer | 61 | High expression in localized and metastatic prostate cancer | (16) |
| Esophagus | Esophageal squamous cell carcinoma (ESCC) | 138 | Higher expression in ESCC tissues than in adjacent normal tissues | (17) |
| Kidney | Kidney cancer | 110 | Higher expression in kidney cancer than in normal kidney tissues; significantly correlated with lymph node metastasis, the clinical stage, and patient prognosis | (18) |
| Brain | Glioblastoma multiforme (GBM) | 22 | Higher expression in GBM specimens than in adjacent noncancer tissues; positive correlation with GBM cell proliferation and migration | (19) |
| Lung | Non-small cell lung cancer (NSCLC) | 71 | Inverse correlation with the prognosis in patients with NSCLC | (20) |
| Breast | Breast cancer | 42 | Inverse correlation with the metastatic capacity | (21) |
| Ovary | Epithelial ovarian carcinoma (EOC) | 208 | Positive correlation with the chemotherapeutic response and overall survival of patients with estrogen receptor α (ERα)-positive tumors | (22) |